5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
J

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the Myriad Of Choices

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Jesus Berdeja
March 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

Related Content

AUTOPLAY
Total Health Conferencing

2021 ASCO Virtual Direct™ Highlights San Francisco

Sat, Jul 31, 2021
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
05:11
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Rel…

Feat. B. Derman
26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Firs…

Feat. K. Anderson
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple M…

10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…

Feat. S. Jagannath
15:22
SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…

Feat. M. Claudio Da Via
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…

Feat. S. Lonial